Avacincaptad Pegol Sodium

Summary

Avacincaptad Pegol Sodium (CHEMBL4297889) is an approved unknown; indicated across 3 conditions including age-related macular degeneration and macular degeneration.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Unknown
• Indications: 3 conditions

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297889
Name	Avacincaptad Pegol Sodium
Type	Unknown
Max phase	4

Also known as: ARC-1905, Arc1905, ARC1905, Avacincaptad pegol sodium, Izervay, AVACINCAPTAD PEGOL SODIUM

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
age-related macular degeneration	2	MONDO:0005150	EFO:0001365
macular degeneration	2	MONDO:0003004	EFO:0009606

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).